A Practical 5-Step Checklist for Evaluating Small Molecule API Suppliers

In 2020, when I took over purchasing for a mid-size biotech, I thought I had sourcing figured out. My background was operations, not chemistry. I figured if a vendor had a GMP cert and a competitive quote, we were good. I was wrong. It wasn't until a $15,000 batch of API arrived with a residual solvent profile that didn't match our spec that I understood the real cost of a bad vendor choice. That mistake cost us two weeks of formulation delays and a very tense call with our CFO.

After five years of managing these relationships—processing 60-80 orders annually across 8 vendors—I’ve come to believe that supplier selection for small molecule APIs is as much about process transparency as it is about price or capacity. This checklist is built for admin buyers and procurement leads who need a repeatable, no-nonsense way to evaluate CDMOs for small molecule work. It covers five steps, from initial screening to post-delivery review.

Step 1: Verify Small Molecule Manufacturing Capability (Beyond the Brochure)

Every CDMO says they handle small molecules. The question is how. I’ve learned to ask for specifics: reactor sizes, isolation methods, and what they do with waste streams. If a vendor can’t easily describe their approach to solvent recovery or recycling—like whether they use an on-site solvent recycler—that’s a red flag. Solvent management isn’t just an environmental issue; it directly impacts batch consistency and cost.

What I mean is that a supplier who lacks in-house solvent recycling will likely pass those costs and risks to you. I once had a vendor whose solvent recovery was outsourced; a logistical hiccup at their third-party facility delayed our delivery by a week. Now I ask upfront: “Do you recycle solvents on-site? What’s your typical recovery rate?” If they pause, I dig deeper.

Step 2: Assess Formulation Expertise (e.g., RPMI-1640 Compatibility)

If you’re sourcing APIs for cell culture media—say, RPMI-1640 formulations—you need a partner who understands the interaction between small molecules and the media matrix. I learned this the hard way. A supplier’s API looked fine on paper, but when we incorporated it into a DMEM batch, the pH shifted unexpectedly.

I now include a specific question in my RFQ: “Can you provide data on your API’s behavior in standard media formulations like RPMI-1640 or DMEM?” Companies like Lonza have built a reputation in this area precisely because they test across formulation contexts. Quality in a vacuum isn’t quality—it has to be quality in your specific use case.

Step 3: Scrutinize the GMP and Regulatory Track Record

GMP certification is table stakes. The real signal is how a vendor handles regulatory changes. I look for three things:

• Recent FDA/EMA inspection reports—if they’re not willing to share a redacted summary, that’s a problem.
• Change control procedures—ask for a recent example of a process change and how it was communicated.
• Impurity profiling—especially for small molecules, residual solvents and genotoxic impurities are a major risk area. Per ICH Q3C guidelines, solvents are classified by risk, and a good CDMO will actively manage their Class 1 and 2 solvents. If a vendor can’t talk about their approach to on-site solvent recycler usage for impurity control, it’s a gap in my view.

I only believed this was essential after ignoring it once. We approved a vendor based on a single audit from two years prior. By the time we placed our order, their facility had undergone a major equipment upgrade—with no notification to us. The first batch failed USP <788> for particulate matter. That was a $12,000 lesson. Now I verify regulatory currency at the time of order, not just at qualification.

Step 4: Evaluate Financial and Supply Chain Stability

This step is often overlooked by admin buyers who focus on technical specs. I’ve learned to check a vendor’s financial health—not in a heavy-handed way, but by asking about raw material sourcing and lead time variability. If a CDMO can’t comfortably discuss their upstream supply chain for key intermediates, it suggests volatility.

Part of me feels awkward asking about finances. Another part remembers the vendor who went silent for three months during a raw material shortage. We had to air-freight an alternative from Europe at double the cost. I reconcile this tension by framing the conversation around risk mitigation: “How do you ensure raw material availability for your top 10 products?” If they don’t have a clear answer, I move on.

Step 5: Run a Small Pilot Order (The Real Test)

Everything before this step is paper-based. The real test is a pilot order. I always start with a small, non-critical batch—maybe 10-20% of our typical volume. This reveals nuances no audit can capture:

• How responsive are they during a real order, not just a sales call?
• Do they provide COAs that match what they promised?
• How do they handle minor issues (e.g., a slight delay in documentation)?

The most surprising insight from these pilots: vendor communication quality directly correlates with batch quality. The vendors who send proactive updates and clear, detailed invoices tend to deliver better products. It’s almost a quality perception halo effect—but the data backs it up in my experience.

Common Mistakes and Final Notes

Three mistakes I see repeatedly in our industry:

1. Over-reliance on price per gram. The cheapest vendor often comes with hidden costs: re-testing, delayed timelines, or compliance remediation. The total cost of ownership—including your team’s management time—is the real metric.
2. Assuming “small molecule” is a uniform category. There’s a world of difference between producing a simple salt and a complex, stereochemically demanding API. Match the vendor’s specialization to your molecule’s complexity.
3. Skipping the solvent management question. As noted, whether a vendor uses an on-site solvent recycler affects cost, sustainability, and consistency. It’s not a niche concern—it’s a core operational factor.

For admin buyers managing relationships at companies like those working with SK Pharma or other CDMO partners, I’d add this: your role is not just procurement—you are the gatekeeper of quality perception for your R&D and manufacturing teams. Every batch that slips through with an issue damages your company’s internal confidence and, eventually, its external reputation.

Is every pilot worth the effort? Sometimes. For a low-volume, non-critical intermediate, maybe a simpler check suffices. But for a molecule going into phase II trials or a high-volume API for a commercial formulation, this checklist has saved me from repeating my 2020 mistake. And I really should document it as a standard operating procedure for our team.